The Directors have the pleasure of presenting the 37^th Annual Report of your Company together with the Audited
Financial Statements for the year ended as on 31^st March, 2025.

PERFORMANCE OF THE COMPANY

Financial Summary (? in Lacs)

The Standalone and Consolidated Financial Statements are prepared in accordance with the Accounting Standards
as prescribed by Institute of Chartered Accountants of India.

The Audited Consolidated Financial Statements are provided in this Annual Report.

MANAGEMENT DISCUSSIONS AND ANALYSIS:

The details of operating performance of the Company for the year, the state of affairs and the key changes in the
operating environment have been analyzed in the Management Discussion and Analysis section which forms a part
of the Annual Report.

APPROPRIATIONS:

DIVIDEND:

The Board of Directors has not recommended any dividend for the year under review. Your Company has recently
purchased a land at Pithampur for its future expansion plans. Considering this significant development, the Board
believes that it is prudent to conserve resources and retain profits to meet the funding requirements of this project
and related growth opportunities.

The expansion at Pithampur is aimed at strengthening our manufacturing capabilities, enhancing operational
efficiency, and creating a strong foundation for long-term growth. By channelizing internal accruals towards this
strategic initiative, we intend to position the Company for sustainable growth and increased shareholder value in
the years to come.

While we understand the importance of dividends to our shareholders, this decision has been taken after careful
consideration to ensure that adequate funds are available for the Company’s expansion and future growth. The
Board is confident that these investments will yield significant returns in the long run, thereby benefiting all
stakeholders.

The Dividend Distribution Policy of the Company is available on the website at www.alpalabs.in
HUMAN RESOURCES:

At Alpa Laboratories Limited, we are committed to nurturing a professional, respectful, and inclusive workplace
where all employees can thrive and contribute meaningfully to the Company’s success. Our HR policies are
designed to align with the Company’s strategic objectives, comply with applicable laws and regulations, and
promote the well-being, development, and engagement of our workforce.

To retain and motivate talent, the Company has implemented several initiatives, including competitive
compensation in line with peer pharmaceutical companies, medical insurance coverage, incentive programs, and
long-term service awards. We strive to create a conducive and professional work environment supported by
participative management, transparent policies and procedures, and robust mechanisms such as the Whistle-blower
Policy and Prevention of Sexual Harassment (POSH) framework. Employee engagement is further enhanced
through activities such as annual sports events, family celebrations, and structured feedback channels.

The Company continues to focus on talent and leadership development. Through cadre and capability-building
interventions, significant efforts were made to strengthen the leadership team and attract the best available talent.
Training and Development programs, on-the-job learning, leadership interactions, and capability-enhancement
initiatives helped sharpen technical, managerial, and behavioural skills across the organization. These measures
have infused renewed energy, enhanced competencies, and built a strong talent pipeline for the future.

Alpa Laboratories Limited is an equal opportunity employer, committed to providing a workplace free of
discrimination and harassment. Employment decisions relating to hiring, promotion, compensation, and career
progression are based solely on merit, qualifications, and business requirements.

Culture remains central to our success. The Company continues to embed its core values of courage,
accountability, development, and teamwork into the workplace. In 2024, we made significant progress in
strengthening our culture to foster a performance-driven, agile, and collaborative organization.

We take pride in our diverse human capital, whose dedication, conviction, and efforts drive the Company’s
achievements. During the year, we welcomed new talent, both experienced professionals and young entrants, and
successfully aligned them with Alpa’s values and culture. The HR function continued to focus on nurturing talent
and strengthening management capabilities.

On the industrial relations front, the Company maintained cordial and constructive relations with its workforce
throughout the year.

SHARE CAPITAL:

The paid-up equity share capital of the company as on 31^st March, 2025 is Rs. 2104.06 Lacs and there is no change
in share capital of the Company as compared to the previous financial year. During the year no further capital were
raised by the company.

SUBSIDIARY, JOINT VENTURE AND ASSOCIATE COMPANIES

There has been no material change in the nature of the business of the subsidiary i.e. Norfolk Mercantile Private
Limited. The company has no subsidiary, which can be considered as material within the meaning of SEBI (Listing
Obligations and Disclosure Requirements) Regulations, 2015.

The Merger of our wholly owned subsidiary i.e. Norfolk Mercantile Private Limited with Alpa Laboratories
Limited is pending before the Hon’ble National Company Law Tribunal, Mumbai.

As required, the financial data of the subsidiary is furnished in the prescribed form AOC-1 as an Annexure to the
Consolidated Financial Statements. Pursuant to the provisions of section 129 (3) of the Companies Act,2013 the
Consolidated Financial Statements of the Company are attached.

The Company is also a partner in Seabright Landmark Projects LLP to the extent of 18% share in profit and
Wealthpile Trading LLP to the extent of 15% share in profit.

INSURANCE

The company is bound to safeguard the assets of the company with the adequate insurance policies and is reviewed
periodically. The Companies planned, properties, equipment and stock are adequately insured against all major
risk including lose on account of business interruption caused due to property damage the company has appropriate
liability to cover product liability and others.

The Company’s manufacturing facilities, properties, equipment and stocks are adequately insured against all major
risks including loss on account of business interruption caused due to property damage. The Company has
appropriate liability insurance covers particularly for product liability, clinical trials and cyber liability. The
Company has also taken Directors’ and Officers’ Liability Policy to provide coverage against the liabilities arising
on them.

BOARD OF DIRECTORS:-

a) Overview:

The Board of Directors of the company is led by the Executive Chairman cum Director and comprises Nine other
directors as on 31^st March, 2025 including one Managing Director, three Executive Directors and Five independent
directors which include two-woman director.

All the Independent Directors of the company have furnished declarations that they meet the criteria of
Independence as laid down under section 149 (6) of the Act and the SEBI (Listing Obligations and Disclosure
Requirements) Regulations,2015 (“Listing Regulations”).

In the opinion of the Board, the directors appointed / re-appointed during the year possess requisite expertise,
integrity and experience (including proficiency) for appointment / reappointment as an Independent Directors of
the Company.

b) Retirement by rotation:

As per the provisions of the Companies Act, 2013, Mr. Shitul Shah, Director, (holding DIN 07883973), retires by rotation at
the ensuing AGM and has offered himself for re-appointment.

c) Remuneration Policy and Board Evaluation:

The Nomination and Remuneration Committee has laid down the criteria for Directors’ appointment and
remuneration including criteria for determining qualification, positive attributes and independence of a director.

The following attributes/criteria for selection have been laid by the Board on the recommendation of the
Committee:

• the candidate should possess the positive attributes such as leadership, entrepreneurship, business advisor or such
other attributes which in the opinion of the Committee are in the interest of the Company;

• the candidate should be free from any disqualification as provided under Sections 164 and 167 of the Companies
Act, 2013;

• the candidate should meet the conditions of being independent as stipulated under the Companies Act, 2013 and
SEBI Listing Obligations and Disclosure Requirements) Regulations, 2015, in case of appointment as an
independent director; and

• the candidate should possess appropriate educational qualification, skills, experience and knowledge in one or
more fields of finance, law, management, sales, marketing, administration, research, corporate governance,
technical operations, infrastructure, medical, social service, professional teaching or such other areas or disciplines
which are relevant for the Company’s business.

d) Familiarisation Program for the Independent Directors:

The Independent Directors have been updated with their roles, rights and responsibilities in the Company by
specifying them in their appointment letter along with necessary documents, reports and internal policies to enable
them to familiarize with the Company’s procedures and practices. The Company endeavors, through presentations
at regular intervals, to familiarize the Independent Directors with the strategy, operations and functioning of the
Company and also with changes in the regulatory environment having a significant impact on the operations of the
Company and the pharmaceutical industry as a whole. Site visits to various plant locations and CSR sites get
organized for the Directors to enable them to understand the operations of and CSR activities carried out by the
Company. The Independent Directors also meet with senior management team of the Company in formal /
informal gatherings.

In Compliance with the requirements of SEBI Regulations, the Company undertook Director’s familiarization
program to familiarize them with their roles, rights and responsibilities as directors, the company’s operations and
other relevant information which would enable them to effectively discharge the responsibilities and functions
conferred on them. Details are placed on the company’s website.

e) Meetings of the Board and Committees thereof:

This information has been furnished under Report on Corporate Governance, which is annexed to this notice.

f) Code of Conduct for Board of Director:

The Company has also adopted a Code of Conduct for Board of Directors. This is also posted on company’s
website. All directors confirmed their abidance with the Code.

g) Key Managerial Personnel

During the financial year under report, the following persons continue to be the Key Managerial Personnel of the
Company:

Mr. Mahendra Singh Chawla - Chairman & Whole-Time Director

Mr. Paresh Chawla - Managing Director

Mr. Pravin Shah - Whole-Time Director

Mr. Shitul Shah - Whole-Time Director

Mr. Vitthal Kothana - Whole-Time Director and ex-Chairman

Mr. Bakulesh Shah - Chief Financial Officer

During the year under review Ms. Swati Bagh Company Secretary has tendered her Resignation w.e.f, 10^th
December 2024 from the position of Company Secretary cum Compliance Officer of the Company and in place of
her Ms. Srashti Chopra has been appointed as a Company Secretary cum Compliance Officer of the Company.

DIRECTOR RESPONSIBILITY STATEMENT:

Pursuant to the requirements under Section 134(5) read with Section 134(3) (c) of the Companies Act, 2013
(“Act”) with respect to Director’s Responsibility Statement, it is hereby confirmed:

a) That in the preparation of the Annual Financial Statements for the year ended as on March 31^st, 2025 the
applicable Accounting Standards had been followed along with proper explanation relating to material departures,
if any.

b) That your Directors have selected such accounting policies as mentioned in the Notes to the financial
statements have been applied consistently and judgments and estimates that are reasonable and prudent have been
made so as to give a true and fair view of the state of affairs of the Company and of the Profit and Loss of the
Company for the year ended as on March 31^st, 2025.

c) That your Directors have taken proper and sufficient care has been taken for the maintenance of adequate
accounting records in accordance with the provisions of the Companies Act, 2013 for safeguarding the assets of the
Company and for preventing and detecting fraud and other irregularities.

d) That your Directors have prepared the Annual Financial Statements have been prepared on a going concern
basis.

e) That your Directors have laid down internal financial controls were followed by the Company and that such
internal financial controls are adequate and were operating effectively.

f) That your Directors have devised proper systems to ensure compliance with the provisions of all applicable
laws were in place and that such systems were adequate and operating effectively.

CORPORATE GOVERNANCE:

As per the requirement of SEBI (Listing Obligations and Disclosure requirements) Regulations, 2015 the
Company has complied with the requirements of Corporate Governance in all material aspects. The report on

Corporate Governance (ANNEXURE-1) together with a certificate of its compliance from a Practicing Company
Secretary, forms part of the report.

As required by Regulation 34 read with Schedule V of the Listing Regulations, a separate Report on Corporate
Governance forms part of the Annual Report. The Report on Corporate Governance also contains certain
disclosures required under the Companies Act, 2013. A certificate from the Secretarial Auditors of the Company
regarding compliance of conditions of Corporate Governance as stipulated under Clause E of Schedule V of the
Listing Regulations forms part of this Report as Annexure 1.

FIXED DEPOSITS:

During the year under review, the Company has not accepted any fixed deposits and as such no amount of
principal or interest on deposit from public was outstanding as on the date of the balance sheet.

AUDIT COMMITTEE:

Details of the Audit Committee along with its constitution and other details are provided in the Report on
Corporate Governance.

AUDITORS

a) STATUTORY AUDITORS

Pursuant to Section 139 (2) of the Companies Act, 2013, read with Companies (Audit and Auditors) Rules, 2014,
the Company at its 34th Annual General Meeting (AGM) held on September 29, 2022, had appointed M/s. C.H
Padliya & Co. Chartered Accountants, Statutory Auditor of the Company, (Firm Registration Number 003151C),
for the period of five years.

The Statutory Auditors’ report forms part of the Annual Report. The notes on financial statements referred to in the
Auditors’ Report are self-explanatory and do not call for any further comments. There are no specifications,
reservations, adverse remarks on disclosure by the statutory auditors in their report. They have not reported any
incident of fraud to the Audit Committee of the Company during the year under review.

b) COST AUDITORS:

Pursuant to the provisions of Section 148 of the Companies Act, 2013, M/s. Sudeep Saxena & Associates, Cost
Accountants (Registration Number 100980) was appointed as Cost Auditors for the financial year 2024-25 to
conduct audit of cost records of the company. The Company is Maintaining cost records and liable for cost audit.

c) SECRETERIAL AUDITOR:

Pursuant to the provisions of Section 204 of the Companies Act, 2013 and Rule 9 of the Companies (Appointment
and Remuneration of Managerial Personnel) Rules, 2014 read with Regulation 24A of SEBI LODR Regulations,
as amended, the Board, subject to the approval of the shareholders, has appointed M/s. Shilpesh Dalal & Co.
Company Secretaries as the Secretarial Auditor for auditing the secretarial records maintained by the Company for
a period of five years i.e. from FY 2025-26 to FY 2029-30. The Secretarial Audit Report is attached (in FORM
No. MR-3) as ANNEXURE-6 to this report.

There are no qualifications, reservations or adverse remarks in the Secretarial Audit Report. Also, pursuant to
Regulation 24A of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Company
has obtained Annual Secretarial Compliance Report from a Practicing Company Secretary and submitted the same
to stock exchanges where the shares of the Company are listed.

d) INTERNAL AUDITORS: M/s S.S Gandhi and Co., Chartered Accountants are the internal auditors of the
Company and to maintain its objectivity and independence, the Internal Auditors report to the Chairman of the
Audit Committee. The scope and authority of the Internal Audit function is clearly defined by the Audit Committee
of the Board. The Internal Auditors monitor and evaluate the efficacy and adequacy of the internal control system
of the Company, its compliance with applicable laws/regulations, accounting procedures and policies. Based on the
reports of the Internal Auditors, corrective actions were undertaken and thereby strengthened the controls.
Significant audit observations and action plans were presented to the Audit Committee of the Board on quarterly
basis.

CORPORATE SOCIAL RESPONSIBILITY:

In compliance with Section 135 of the CA 2013 read with the Companies (Corporate Social Responsibility Policy)
Rules 2014, the Company has established the Corporate Social Responsibility Committee (CSR Committee).

The Board on the recommendation of CSR Committee adopted a CSR Policy. The same is available on Company’s
website at https://www.alpalabs.in. The CSR objectives are designed to serve societal, local and national goals in
the locations that we operate in, creating a significant and sustained impact on local communities.

During the year 2024-25 the company incurred CSR Expenditure of Rs. 40 Lakhs. The Company is always being a
committed good corporate citizen, as a part of its social responsibility, the company undertakes various activities
for the benefit of needy people, company has maintained good relationship with the charitable organization and
support for the people to improve the living conditions. During the year under review Company has supported
education, old age homes and promotional of Social Activities undertaken by charitable institutions and
organizations.

An abstract on Company CSR activities is furnished as ANNEXURE-2 to this report.

PARTICULARS OF LOANS, GUARANTEES AND INVESTMENTS:

Details of loans, guarantees and investments covered under the provisions of Section 186 of the Companies Act,
2013 are given in the notes to the financial statement.

PARTICULARS OF CONTRACTS AND RELATED PARTY TRANSACTIONS:

In line with the requirements of the Companies Act, 2013 and SEBI (LODR) Regulations, 2015, Company has
formulated a policy on Related Party Transactions. All related party transactions that are entered during the
financial year were on arm’s length basis and in the ordinary course of business. There were no materially
significant transactions with Related Parties during the financial year 2024-25. The policy of related party
transaction, Board had approved policies on Related Party Transactions and the same have been uploaded on the
Company’s website, under the web link: www.alpalabs.in.

Related party transactions are disclosed in the notes to the Financial Statements. Prescribed Form No. AOC-2
pursuant to clause (h) of sub-section (3) of Section 134 of the Act and Rule 8(2) of the Companies (Accounts)
Rules, 2014 is furnished as ANNEXURE- 3 to this report.

SAFETY, ENVIRONMENT AND HEALTH:

The Company considers safety, environment and health as the management responsibility; regular training
programmes are carried out on safety, health and environment.

PREVENTION OF SEXUAL HARRASMENT AT WORK PLACE:

The Company is committed to provide a healthy environment to all employees and thus does not tolerate any
discrimination and/or harassment in any form. The Company has in place a Prevention of Sexual Harassment
(POSH) policy in line with the requirements of the Sexual Harassment of Women at Workplace (Prevention,
Prohibition and Redressal) Act, 2013. Frequent communication of this policy is done at regular intervals to woman
employees.

The Company has setup an Internal Complaints Committee (ICC) at location where it operates in India. ICC has
representation of men and women and is chaired by senior lady and has an external women representation.

No Complaints has received during the year under review 2025.

WHISTLE BLOWER POLICY/VIGIL MECHANISM:

Pursuant to Section 177(9) of the Companies Act, 2013 read with Rule 7 of the Companies (Meetings of Board and
its Powers) Rules, 2014 and Regulation 22 of the SEBI (LODR) Regulation, 2015, the Board of Directors had
approved and regularly amended from time to time the Policy on Vigil Mechanism/ Whistle Blower

The said mechanism provides adequate safeguards against victimization of employees who use the vigil
mechanism and provides direct access to the Audit Committee. Also the Code of Business Conduct (Code) lays
down important corporate ethical practices that shape the Company’s value system and business functions and
represents cherished values of the Company.

Whistleblower Policy and Code of Business Conduct has been hosted on Company’s website link www.alpalabs.in

Your Company hereby affirms that no personnel have been denied access to the Chairman of the Audit Committee
and that no complaints were received during the year.

CODE OF CONDUCT FOR PREVENTION OF INSIDER TRADING:

The Company has built a strong policy on the code of conduct for prevention of insider trading for the employees
as well as for specified employees. The same is easily accessible from the company website (www.alpalabs.in).

SIGNIFICANT AND MATERIAL ORDERS PASSED BY THE REGULATORS OR COURTS:

There are no significant and material orders passed by the Regulators or Courts or Tribunals, which would impact
the going concern status of the Company.

MANAGERIAL REMUNERATION AND PARTICULARS OF EMPLOYEES:

The Remuneration policy covers the remuneration for the Directors (Chairman, Managing Director, Whole-time
directors, Independent Directors and other non-executive Directors) and other employees (under senior
management cadre and management cadre). The Policy has been formulated with the following key objectives:

To ensure that employee remuneration is in alignment with business strategy & objectives, organization values and
long-term interests of the organization.

To ensure objectivity, fairness and transparency in determination of employee’s remuneration.

To ensure the level and composition of remuneration are reasonable and sufficient to attract, retain and motivate a
high-performance workforce and are in compliance with all applicable laws.

It covers various heads of remuneration including benefits for Directors and employees. It also covers the process
followed with respect to annual performance reviews and variables considered for revision in the remuneration.
The said Policy is available on the website of the Company www.alpalabs.in.

Details of remuneration as required under Section 197 (12) of the Companies Act, 2013 read with rules 5(1) of the
Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 is ANNEXURE- 4 to this
report.

CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION AND FOREIGN EXCHANGE
EARNINGS AND OUTGO:

The particulars prescribed under Section 134 of the Companies Act, 2013 read with Rule 8(3) of the Companies
(Accounts) Rules, 2014, relating to Conservation of Energy, Technology Absorption, Foreign Exchange Earnings
and Outgo are furnished in ANNEXURE-5 to this Report.

EXTRACT OF ANNUAL RETURN:

In terms of Section 92(3) of the Companies Act, 2013 and Rule 12 of the Companies (Management and
Administration) Rules, 2014, the Annual Return of the Company is available on the website of the Company at the
link https://alpalabs.in/information/.

APPRECIATION AND ACKNOWLEDGEMENTS:

Your directors appreciate the trust repose by the medical fraternity and look forward to their continue patronage.
The Directors are grateful and pleased to place on record their appreciation for the excellent support guidance and
co-operation extended by the Government Authorities and Agencies, bankers, customers, dealers and suppliers and
also the valuable assistance and advice received from the Statutory Auditors, Companies Secretarial Auditors,
Legal advisors, and all the shareholders. The Directors also wish to thank all the employees for their contribution,
support and continued co-operation throughout the year.

On behalf of the Board of Directors of
Alpa Laboratories Limited

Pigdamber, Rau. Paresh Chawla MS Chawla

13^th August, 2025 Managing Director Director

DIN-00520411 DIN-00362058